Halberd (Halberd) EV-to-EBITDA : (As of May. 22, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Halberd EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Halberd's enterprise value is $0.38 Mil. Halberd does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Jul. 2023. Therefore, GuruFocus does not calculate Halberd's EV-to-EBITDA at this moment.

The historical rank and industry rank for Halberd's EV-to-EBITDA or its related term are showing as below:

HALB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.39 Med: 0 Max: 0
Current: -0.85

HALB's EV-to-EBITDA is ranked worse than
100% of 449 companies
in the Biotechnology industry
Industry Median: 9.97 vs HALB: -0.85

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Halberd's stock price is $0.0088. Halberd does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jul. 2023. Therefore, GuruFocus does not calculate Halberd's PE Ratio at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Halberd EV-to-EBITDA Historical Data

The historical data trend for Halberd's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd EV-to-EBITDA Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

EV-to-EBITDA

-4.05

-12.00

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
EV-to-EBITDA	-	-4.05	-12.00

Competitive Comparison of Halberd's EV-to-EBITDA

For the Biotechnology subindustry, Halberd's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Halberd's EV-to-EBITDA falls into.

Halberd EV-to-EBITDA Calculation

Halberd's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	0.377	/
	=

Halberd (OTCPK:HALB) EV-to-EBITDA Explanation

Halberd's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.0088	/
	=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Halberd EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Halberd's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236